Skip to contentN
Northwest Biotherapeutics Inc
N
NWBONorthwest Biotherapeutics Inc Q3 2014 · 10-Q
Revenue$582.00K$582.00K+45.5% vs Q3 2013 Net Income-$21.04M-$21.04MN/M vs Q3 2013 EPS Diluted-$0.35-$0.35N/M vs Q3 2013 Operating Income-$26,608,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Northwest Biotherapeutics Inc · CIK 1072379 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$30,814,000N/M Margins · derivedOperating margin-4571.8%−708.8 pt vs Q3 2013
Net margin-3615.6%+2111.9 pt vs Q3 2013
ended Sep 30, 2014 · filed Nov 19, 2014 · 50 d after period end